NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach.

INTRODUCTION

Diabetes Mellitus (DM) constitutes a global epidemic and is one of the top ten leading causes of mortality (WHO, 2019), projected to rank seventh by 2030. The US National Diabetes Statistics Report (2021) states that 38.4 million Americans have diabetes. Dipeptidyl Peptidase-4 (DPP-4) is an FDA-approved target for the treatment of type 2 diabetes mellitus (T2DM). However, current DPP-4 inhibitors may cause adverse effects, including gastrointestinal issues, severe joint pain (FDA safety warning), nasopharyngitis, hypersensitivity, and nausea. Moreover, the development of novel drugs and the assessment of DPP-4 inhibition are both costly and often impractical. These challenges highlight the urgent need for efficient approaches to facilitate the discovery and optimization of safer and more effective DPP-4 inhibitors.

METHODOLOGY

Quantitative Structure-Activity Relationship (QSAR) modeling is a widely used computational approach for evaluating the properties of chemical substances. In this study, we employed a Neuro-symbolic (NeSy) approach, specifically the Logic Tensor Network (LTN), to develop a DPP-4 QSAR model capable of identifying potential small-molecule inhibitors and predicting bioactivity classification. For comparison, we also implemented baseline models using Deep Neural Networks (DNNs) and Transformers. A total of 6,563 bioactivity records (SMILES-based compounds with IC values) were collected from ChEMBL, PubChem, BindingDB, and GTP. Feature sets used for model training included descriptors (CDK Extended-PaDEL), fingerprints (Morgan), chemical language model embeddings (ChemBERTa-2), LLaMa 3.2 embedding features, and physicochemical properties.

RESULTS

Among all tested configurations, the Neuro-symbolic QSAR model (NeSyDPP-4) performed best using a combination of CDK extended and Morgan fingerprints. The model achieved an accuracy of 0.9725, an F1-score of 0.9723, an ROC AUC of 0.9719, and a Matthews correlation coefficient (MCC) of 0.9446. These results outperformed the baseline DNN and Transformer models, as well as existing state-of-the-art (SOTA) methods. To further validate the robustness of the model, we conducted an external evaluation using the Drug Target Common (DTC) dataset, where NeSyDPP-4 also demonstrated strong performance, with an accuracy of 0.9579, an AUC-ROC of 0.9565, a Matthews Correlation Coefficient (MCC) of 0.9171, and an F1-score of 0.9577.

DISCUSSION

These findings suggest that the NeSyDPP-4 model not only delivered high predictive performance but also demonstrated generalizability to external datasets. This approach presents a cost-effective and reliable alternative to traditional vivo screening, offering valuable support for the identification and classification of biologically active DPP-4 inhibitors in the treatment of type 2 diabetes mellitus (T2DM).